leadf
logo-loader
LSE:STX FRA:1JS

Shield Therapeutics PLC

Receive alerts
Market:
LSE
Market Cap:
£90.67 m
Price
42.00 GBX
Change
5.00%
52 weeks high
144.78
52 weeks low
31.00

In brief

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

Snapshot

  • Shield Therapeutics pleased with progress to date on US launch of Accrufer
  • Shield Therapeutics' present drive for US launch success of iron deficiency product Accrufer